Fempatch

Business Editors/Health & Medical Writers

BIOWIRE2K

RICHMOND, Va.--(BW HealthWire)--Nov. 26, 2001

Insmed Incorporated (NASDAQ: INSM) today announced the election of Randall W. Whitcomb, M.D. to its board of directors.

Dr. Whitcomb is currently Head of Therapeutics for QuatRx Pharmaceuticals.

Before joining QuatRx, Dr. Whitcomb was vice president of drug development and clinical research at Parke-Davis.

At Parke-Davis, Dr. Whitcomb's areas of responsibility included development and approval of products for diabetes (including Rezulin(R)) and women's health care (FemPatch(R) and femhrt(R)), as well as oversight of earlier stage compounds for diabetic neuropathy, osteoporosis, inflammation and gastrointestinal diseases. He also played key roles in two Food and Drug Administration Advisory Committee presentations, four New Drug Applications, two Market Authorization Applications and numerous Investigational New Drug applications.

"I am pleased to join Insmed's Board," said Dr. Whitcomb. "I have been consulting with the Company for over a year and am very excited about its products. The potential markets for its drugs are enormous and I am very excited about their possibilities." "We are delighted that Randy has agreed to assume this new role," said Geoffrey Allan, Ph.D., Insmed's president, chief executive officer and chairman. "He has extensive experience and insight in the drug approval process and will be an invaluable asset as our product candidates begin Phase III clinical trials and the approval process."

About Insmed Incorporated

Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of type 2 diabetes and other metabolic and endocrine disorders associated with insulin resistance. The Company's lead product candidate, INS-1, is an orally active small molecule that restores insulin sensitivity to tissue. The Company is developing INS-1 for the treatment of type 2 diabetes and polycystic ovary syndrome, a significant women's health disorder. The Company's second product candidate, SomatoKine(R), is a recombinant human protein that is targeted towards the management of both type 1 and type 2 diabetics who are less sensitive to insulin therapy. Further information is available at www.insmed.com.

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.

COPYRIGHT 2001 Business Wire
COPYRIGHT 2001 Gale Group